Shots:

• The companies reported the initiation of a P-II dose-finding study assessing the safety- reactogenicity- and immunogenicity of two injections given 21 days apart in 720 adults aged ≥18yrs.
• The P-II study assesses the potential for refined antigen formulation to achieve an optimal immune response- including in older adults. If P-II results are positive- the P-III study is expected to be initiated in Q2’21 with vaccine anticipated to be available in Q4’21
• In parallel to the P-II study- Sanofi has commenced development work against new variants- which will be used to inform the next stages of the Sanofi/GSK development program

 ­ Ref: Sanofi | Image: Sanofi